These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1253807)

  • 1. Phenazone metabolism in patients with liver disease.
    Andreasen PB; Greisen G
    Eur J Clin Invest; 1976 Jan; 6(1):21-6. PubMed ID: 1253807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of metronidazole on phenazone metabolism].
    Staiger C; Wang NS; de Vries J; Weber E
    Arzneimittelforschung; 1984; 34(1):89-91. PubMed ID: 6538427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.
    St Peter JV; Awni WM
    Clin Pharmacokinet; 1991 Jan; 20(1):50-65. PubMed ID: 2029802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug absorption and hepatic drug metabolism in patients with different types of intestinal shunt operation for obesity. A study with phenazone.
    Andreasen PB; Danö P; Kirk H; Greisen G
    Scand J Gastroenterol; 1977; 12(5):531-5. PubMed ID: 918547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of antipyrine-dependence of quantitative liver function.
    Andreasen PB; Ranek L; Statland BE; Tygstrup N
    Eur J Clin Invest; 1974 Apr; 4(2):129-34. PubMed ID: 4832718
    [No Abstract]   [Full Text] [Related]  

  • 7. Accuracy and clinical utility of simplified tests of antipyrine metabolism.
    Farrell GC; Zaluzny L
    Br J Clin Pharmacol; 1984 Oct; 18(4):559-65. PubMed ID: 6487495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.
    Fabre D; Bressolle F; Goméni R; Bouvet O; Dubois A; Raffanel C; Gris JC; Galtier M
    Clin Pharmacokinet; 1993 Apr; 24(4):333-43. PubMed ID: 8491059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravenous loading with galactose as a liver function test. Methods and clinical value].
    Kuntz HD; Kuntz E
    Fortschr Med; 1983 Jun; 101(21):999-1004. PubMed ID: 6873856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of acute biliary pancreatitis on liver metabolism of phenazone].
    Hartleb M; Nowak A; Nowakowska-Duława E; Mańczyk I; Becker A; Kacperek T
    Pol Arch Med Wewn; 1990 Mar; 83(3):104-10. PubMed ID: 2216933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antipyrine excretion and aminopyrine breath test: use and significance in the assessment of liver function].
    Gugler R
    Z Gastroenterol; 1987 Mar; 25 Suppl 2():51-6. PubMed ID: 3590907
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
    Eichelbaum M; Ochs HR; Roberts G; Somogyi A
    Arzneimittelforschung; 1982; 32(5):575-8. PubMed ID: 7201837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of pindolol in liver disease.
    Ohnhaus EE; Münch U; Meier J
    Eur J Clin Pharmacol; 1982; 22(3):247-51. PubMed ID: 7106158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in drug elimination under the influence of perazine therapy (author's transl)].
    Petruch F; Schüppel R; Breyer U
    Arzneimittelforschung; 1976; 26(6):1154-5. PubMed ID: 9113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
    Homeida M; Roberts CJ; Halliwell M; Read AE; Branch RA
    Gut; 1979 Jul; 20(7):596-601. PubMed ID: 488757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
    Branch RA; James JA; Read AE
    Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone--a novel galactose single-point method as a measure of residual liver function.
    Hu OY; Tang HS; Chang CL
    Biopharm Drug Dispos; 1994 Oct; 15(7):563-76. PubMed ID: 7849232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Michaëlis--Menten kinetics of phenazone elimination in the perfused pig liver.
    Andreasen B; Tonnesen K; Rabol A; Keiding S
    Acta Pharmacol Toxicol (Copenh); 1977 Jan; 40(1):1-13. PubMed ID: 576352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.